INDY | CAS 1169755-45-6 - Order from AdipoGen

More Information
Product Details
Synonyms	(1Z)-1-(3-Ethyl-5-hydroxy-2(3H)-benzothiazolylidene)-2-propanone
Product Type	Chemical
Properties
Formula	C₁₂H₁₃NO₂S
MW	235.3
CAS	1169755-45-6
Purity Chemicals	≥98% (HPLC)
Appearance	White to off-white solid.
Solubility	Soluble in DMSO (10mg/ml).
Identity	Determined by ¹H-NMR.
InChi Key	GCSZJMUFYOAHFY-SDQBBNPISA-N
Smiles	OC1=CC=C(S/C(N2CC)=C\C(C)=O)C2=C1
Shipping and Handling
Shipping	AMBIENT
Short Term Storage	+4°C
Long Term Storage	-20°C
Handling Advice	Keep cool and dry.
Use/Stability	Stable for at least 2 years after receipt when stored at -20°C.
Documents
MSDS	Download PDF
Product Specification Sheet
Datasheet	Download PDF

Description

Potent and selective ATP-competitive DYRK1A and DYRK1B inhibitor (IC₅₀=240nM and 230nM respectively). Binds at the ATP-binding cleft of the enzyme.
Inhibits also DYRK2, DYRK3, CLK1, CLK4, casein kinase 1 (CSNK1D) and PIM1 (>90% inhibition at the same concentration).
Reverses aberrant tau-phosphorylation and rescues repressed calcineurin/NFAT signaling.
Impairs the self-renewal capacity of neural stem cells and glioblastoma tumor-initiating cells.
Shown to induce regeneration and expansion of rat and adult human β-cells in vivo or ex vivo.

Product References

Development of a novel selective inhibitor of the Down syndrome-related kinase Dyrk1A: Y. Ogawa, et al.; Nat. Commun. 1, 86 (2010)
Inhibition of DYRK1A destabilizes EGFR and reduces EGFR-dependent glioblastoma growth: N. Pozo, et al.; J. Clin. Invest. 123, 2475 (2013)
A high-throughput chemical screen reveals that harmine-mediated inhibition of DYRK1A increases human pancreatic beta cell replication: P. Wang, et al.; Nat. Med. 21, 383 (2015)
Comparative Efficacy and Selectivity of Pharmacological Inhibitors of DYRK and CLK Protein Kinases: M.F. Lindberg, et al.; J. Med. Chem. ahead of print (2023)

Call	+41 61 926 6040
Fax	+41 61 926 6049